{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:32:08Z","timestamp":1789173128103,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00392-026-02845-2","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:22:46Z","timestamp":1768818166000},"page":"1378-1388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic dysfunction associated steatotic liver disease, cardiometabolic multimorbidity and mortality: evidence from the UK biobank"],"prefix":"10.1007","volume":"115","author":[{"given":"Can","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-1685","authenticated-orcid":false,"given":"Yu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-9674","authenticated-orcid":false,"given":"Xiaoyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2845_CR1","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1016\/s2468-2667(17)30074-9","volume":"2","author":"M Kivim\u00e4ki","year":"2017","unstructured":"Kivim\u00e4ki M, Kuosma E, Ferrie JE et al (2017) Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120\u2008813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health 2:e277\u2013e285. https:\/\/doi.org\/10.1016\/s2468-2667(17)30074-9","journal-title":"Lancet Public Health"},{"key":"2845_CR2","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1093\/eurheartj\/ehab413","volume":"42","author":"Y Han","year":"2021","unstructured":"Han Y, Hu Y, Yu C et al (2021) Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study. Eur Heart J 42:3374\u20133384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab413","journal-title":"Eur Heart J"},{"key":"2845_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46686-x","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhuang Z, Li Y et al (2024) Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity. Nat Commun 15:2451. https:\/\/doi.org\/10.1038\/s41467-024-46686-x","journal-title":"Nat Commun"},{"key":"2845_CR4","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/hep.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78:1966\u20131986. https:\/\/doi.org\/10.1097\/hep.0000000000000520","journal-title":"Hepatology"},{"key":"2845_CR5","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79:1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"key":"2845_CR6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313\u20131321. https:\/\/doi.org\/10.1002\/hep.20701","journal-title":"Hepatology"},{"key":"2845_CR7","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.31420","volume":"73","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Rinella ME, Sanyal AJ et al (2021) From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology (Baltimore, Md) 73:1194\u20131198. https:\/\/doi.org\/10.1002\/hep.31420","journal-title":"Hepatology (Baltimore, Md)"},{"key":"2845_CR8","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.jhep.2020.08.028","volume":"73","author":"V Ratziu","year":"2020","unstructured":"Ratziu V, Rinella M, Beuers U et al (2020) The times they are a-changin' (for NAFLD as well). J Hepatol 73:1307\u20131309. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.028","journal-title":"J Hepatol"},{"key":"2845_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M et al (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908\u2013922. https:\/\/doi.org\/10.1038\/s41591-018-0104-9","journal-title":"Nat Med"},{"key":"2845_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03080-6","volume":"21","author":"Y Jia","year":"2023","unstructured":"Jia Y, Li D, You Y et al (2023) Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK biobank. BMC Med 21:398. https:\/\/doi.org\/10.1186\/s12916-023-03080-6","journal-title":"BMC Med"},{"key":"2845_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H (2024) MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73:691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595","journal-title":"Gut"},{"key":"2845_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee HH, Lee HA, Kim EJ et al (2024) Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut 73:533\u2013540. https:\/\/doi.org\/10.1136\/gutjnl-2023-331003","journal-title":"Gut"},{"key":"2845_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111891","volume":"217","author":"R Mollace","year":"2024","unstructured":"Mollace R, Longo S, Nardin M et al (2024) Role of MASLD in CVD: a review of emerging treatment options. Diabetes Res Clin Pract 217:111891. https:\/\/doi.org\/10.1016\/j.diabres.2024.111891","journal-title":"Diabetes Res Clin Pract"},{"key":"2845_CR14","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM et al (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore, Md) 77:1335\u20131347. https:\/\/doi.org\/10.1097\/hep.0000000000000004","journal-title":"Hepatology (Baltimore, Md)"},{"key":"2845_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1433807","volume":"11","author":"X Gu","year":"2024","unstructured":"Gu X, Gao D, Zhou X et al (2024) Association between fatty liver index and cardiometabolic multimorbidity: evidence from the cross-sectional national health and nutrition examination survey. Front Cardiovasc Med 11:1433807. https:\/\/doi.org\/10.3389\/fcvm.2024.1433807","journal-title":"Front Cardiovasc Med"},{"key":"2845_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","volume":"71","author":"TG Simon","year":"2022","unstructured":"Simon TG, Roelstraete B, Hagstr\u00f6m H et al (2022) Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 71:1867\u20131875. https:\/\/doi.org\/10.1136\/gutjnl-2021-325724","journal-title":"Gut"},{"key":"2845_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, Targher G, Byrne CD et al (2023) An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int 17:773\u2013791. https:\/\/doi.org\/10.1007\/s12072-023-10543-8","journal-title":"Hepatol Int"},{"key":"2845_CR18","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N et al (2015) UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12:e1001779. https:\/\/doi.org\/10.1371\/journal.pmed.1001779","journal-title":"PLoS Med"},{"key":"2845_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230x-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L et al (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33. https:\/\/doi.org\/10.1186\/1471-230x-6-33","journal-title":"BMC Gastroenterol"},{"key":"2845_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091877","author":"M Castellana","year":"2021","unstructured":"Castellana M, Donghia R, Guerra V et al (2021) Performance of fatty liver index in identifying non-alcoholic fatty liver disease in population studies. A meta-analysis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10091877","journal-title":"J Clin Med"},{"key":"2845_CR21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (Baltimore Md) 45:846\u2013854. https:\/\/doi.org\/10.1002\/hep.21496","journal-title":"Hepatology (Baltimore Md)"},{"key":"2845_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43:1317\u20131325. https:\/\/doi.org\/10.1002\/hep.21178","journal-title":"Hepatology"},{"key":"2845_CR23","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/gut.2007.146019","volume":"57","author":"SA Harrison","year":"2008","unstructured":"Harrison SA, Oliver D, Arnold HL et al (2008) Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57:1441\u20131447. https:\/\/doi.org\/10.1136\/gut.2007.146019","journal-title":"Gut"},{"key":"2845_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM (2011) Multiple imputation using chained equations: issues and guidance for practice. Stat Med 30:377\u2013399. https:\/\/doi.org\/10.1002\/sim.4067","journal-title":"Stat Med"},{"key":"2845_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/978-1-4939-7274-6_28","volume":"1666","author":"CM Stein","year":"2017","unstructured":"Stein CM, Morris NJ, Hall NB et al (2017) Structural equation modeling. Methods Mol Biol 1666:557\u2013580. https:\/\/doi.org\/10.1007\/978-1-4939-7274-6_28","journal-title":"Methods Mol Biol"},{"key":"2845_CR26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S et al (2021) NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 110:921\u2013937. https:\/\/doi.org\/10.1007\/s00392-020-01709-7","journal-title":"Clin Res Cardiol"},{"key":"2845_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2022.07.010","volume":"355","author":"Z Wang","year":"2022","unstructured":"Wang Z, Ye M, Zhang XJ et al (2022) Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis 355:30\u201344. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.07.010","journal-title":"Atherosclerosis"},{"key":"2845_CR28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/liv.15856","volume":"44","author":"R Song","year":"2024","unstructured":"Song R, Li Z, Zhang Y et al (2024) Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int 44:1051\u20131060. https:\/\/doi.org\/10.1111\/liv.15856","journal-title":"Liver Int"},{"key":"2845_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/s2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G et al (2021) Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:903\u2013913. https:\/\/doi.org\/10.1016\/s2468-1253(21)00308-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2845_CR30","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/s2666-7568(23)00054-5","volume":"4","author":"Y Jin","year":"2023","unstructured":"Jin Y, Liang J, Hong C et al (2023) Cardiometabolic multimorbidity, lifestyle behaviours, and cognitive function: a multicohort study. Lancet Healthy Longev 4:e265\u2013e273. https:\/\/doi.org\/10.1016\/s2666-7568(23)00054-5","journal-title":"Lancet Healthy Longev"},{"key":"2845_CR31","doi-asserted-by":"publisher","first-page":"zwaf247","DOI":"10.1093\/eurjpc\/zwaf247","volume":"26","author":"M Huang","year":"2025","unstructured":"Huang M, Fu R, Zhao X et al (2025) Life's essential 8 and progression of cardiometabolic multimorbidity trajectory: a prospective study of UK biobank. Eur J Prev Cardiol 26:zwaf247. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf247","journal-title":"Eur J Prev Cardiol"},{"key":"2845_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082615","volume":"14","author":"I Ioakeim-Skoufa","year":"2025","unstructured":"Ioakeim-Skoufa I, Ledesma-Calvo R, Moreno-Juste A et al (2025) Charting the pathways of cardiometabolic multimorbidity: a systematic review of clinical trajectories. J Clin Med 14:2615. https:\/\/doi.org\/10.3390\/jcm14082615","journal-title":"J Clin Med"},{"key":"2845_CR33","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/s0140-6736(18)30994-2","volume":"391","author":"GBD 2016 Healthcare Access and Quality Collaborators","year":"2018","unstructured":"GBD 2016 Healthcare Access and Quality Collaborators (2018) Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet (London, England) 391:2236\u20132271. https:\/\/doi.org\/10.1016\/s0140-6736(18)30994-2","journal-title":"Lancet (London, England)"},{"key":"2845_CR34","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1097\/hep.0000000000000386","volume":"78","author":"H Tilg","year":"2023","unstructured":"Tilg H, Adolph TE, Tacke F (2023) Therapeutic modulation of the liver immune microenvironment. Hepatology (Baltimore, Md) 78:1581\u20131601. https:\/\/doi.org\/10.1097\/hep.0000000000000386","journal-title":"Hepatology (Baltimore, Md)"},{"key":"2845_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","volume":"42","author":"PR Lawler","year":"2021","unstructured":"Lawler PR, Bhatt DL, Godoy LC et al (2021) Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J 42:113\u2013131. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa099","journal-title":"Eur Heart J"},{"key":"2845_CR36","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jhep.2023.08.023","volume":"79","author":"X Chen","year":"2023","unstructured":"Chen X, Chen S, Pang J et al (2023) Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux. J Hepatol 79:1491\u20131501. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.023","journal-title":"J Hepatol"},{"key":"2845_CR37","doi-asserted-by":"publisher","first-page":"1012887","DOI":"10.3389\/fphys.2022.1012887","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J, Wang M, Wu Y et al (2022) Serum high-sensitive C-reactive protein is a simple indicator for all-cause among individuals with MAFLD. Front Physiol 13:1012887. https:\/\/doi.org\/10.3389\/fphys.2022.1012887","journal-title":"Front Physiol"},{"key":"2845_CR38","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","volume":"36","author":"T Bo","year":"2024","unstructured":"Bo T, Gao L, Yao Z et al (2024) Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab 36:947\u2013968. https:\/\/doi.org\/10.1016\/j.cmet.2024.04.006","journal-title":"Cell Metab"},{"key":"2845_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02108-x","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Yang P, Ye J et al (2024) Updated mechanisms of MASLD pathogenesis. Lipids Health Dis 23:117. https:\/\/doi.org\/10.1186\/s12944-024-02108-x","journal-title":"Lipids Health Dis"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02845-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:05:18Z","timestamp":1783494318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02845-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2845"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02845-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval of UK Biobank study was approved by NHS National Research Ethics Service (16\/NW\/0274).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}